DeepMed Research

CHINA MEDICAL UNIVERSITY

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Private

Employees: -

Market Cap: -

Website: http://english.cmu.edu.tw

Clinical Trials

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4

Not yet recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: Liposome Irinotecan
Drug: Platinum
Drug: Tislelizumab
Drug: Anlotinib

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: China Medical University, China

Target Recruit Count: 31

Registration Number: NCT06951841

Locations: 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
HER2 + Gastric Cancer
PD-L1 Positive
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Interventions: Drug: Trastuzumab
Drug: Capecitabine
Drug: Apatinib
Drug: Adebrelimab
Drug: SHR-A1811
Drug: Oxaliplatin
Drug: S-1
Drug: SHR-A1904
Drug: SHR-1701
Drug: zolbetuximab

First Posted Date: 2025-03-18

Last Posted Date: 2025-03-18

Lead Sponsor: China Medical University, China

Target Recruit Count: 140

Registration Number: NCT06881017

Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation

Not Applicable

Recruiting

Conditions: The Direction of Blocker Placement

Interventions: Device: the tip opening angle to the left
Device: the tip opening angle to the right

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-16

Lead Sponsor: China Medical University, China

Target Recruit Count: 96

Registration Number: NCT06595043

Locations: 🇨🇳
Wenfei Tan, Shenyang, China
🇰🇷
Konkuk University School of Medicine, Seoul, Korea, Republic of
🇷🇸
the University Clinical Center of Serbia, Belgrade, Serbia

Children With High Genetic Susceptibility Benefit More From Short-term Physical Activity Interventions

Not Applicable

Completed

Conditions: Physical Inactivity
Obesity, Childhood

Interventions: Behavioral: 4-week MVPA intervention

First Posted Date: 2024-09-04

Last Posted Date: 2024-09-04

Lead Sponsor: China Medical University, China

Target Recruit Count: 140

Registration Number: NCT06583421

Locations: 🇨🇳
China Medical University, Shenyang, China

Dietary Intervention for Low Free Sugars in Children With Non-alcoholic Fatty Liver Disease

Not Applicable

Completed

Conditions: NAFLD
Low-free Sugar Dietary
Child Obesity

Interventions: Behavioral: Dietary intervention for low free sugars

First Posted Date: 2024-08-30

Last Posted Date: 2024-08-30

Lead Sponsor: China Medical University, China

Target Recruit Count: 146

Registration Number: NCT06579729

Locations: 🇨🇳
China Medical University, Shenyang, China

Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia

Phase 4

Recruiting

Conditions: Oxygenation Index

Interventions: Drug: 80% Oxygen
Drug: 40% Oxygen

First Posted Date: 2024-04-11

Last Posted Date: 2024-10-08

Lead Sponsor: China Medical University, China

Target Recruit Count: 1098

Registration Number: NCT06359106

Locations: 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳
Sichuan Provincial People's Hospital, Chendu, China

and more 13 locations

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer, Metastatic

Interventions: Biological: BioTTT001 intraperitoneal infusion
Drug: SOX regimen
Drug: toripalimab

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-29

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT06283121

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Biological: T3011 hepatic artery infusion
Drug: toripalimab
Drug: regorafenib

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-29

Lead Sponsor: China Medical University, China

Target Recruit Count: 8

Registration Number: NCT06283303

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Biological: BioTTT001 hepatic artery infusion
Drug: toripalimab
Drug: regorafenib

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-29

Lead Sponsor: China Medical University, China

Target Recruit Count: 40

Registration Number: NCT06283134

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Durvalumab

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT06255262

Locations: 🇨🇳
Anshan Cancer Hospital, Anshan, Liaoning, China
🇨🇳
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy